Abstract-Primary aldosteronism affects ≈5% to 10% of hypertensive patients and has unilateral and bilateral forms.
H ypertension affects ≈1 in 3 adults 1 and is a major risk factor for stroke and heart disease, contributing to 1000 deaths per day, 2 which is comparable to that of malignant diseases. 3 Primary aldosteronism (PA) affects ≈5% to 10% of all hypertensive patients. 4, 5 Appropriate therapy of PA is important as PA patients are at greater risk of stroke, coronary artery disease, atrial fibrillation, and heart failure. 6 PA is classified into 2 subtypes based on laterality assessed by adrenal vein sampling 4, 7 ( Figure 1 ). Unilateral PA is predominantly caused by aldosterone-producing adenomas (APA) that are detectable by computed tomography (CT) and account for ≈30% of PA 5 . A small percentage of unilateral PA results from CT-undetected aldosteroneproducing areas, termed multiple unilateral adrenocortical micronodules, or microAPA. 8, 9 Similar to APA, such micronodules exhibit high CYP11B2 expression (aldosterone synthase, the enzyme responsible for the final step of aldosterone biosynthesis).
The advent of next-generation sequencing (NGS) has led to the identification of recurrent somatic mutations in APA. Approximately half of APA harbor somatic mutations in KCNJ5, which encodes potassium inwardly rectifying channel, subfamily J, member 5, while an additional 10% to 15% of APA harbor somatic mutations in CACNA1D (encoding calcium channel, voltage-dependent, L-type, α1D-subunit), ATP1A1 (encoding ATPase, Na/K transporting, 1-polypeptide A), or ATP2B3 (encoding ATPase, Ca2-transporting, plasma membrane 3), respectively. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In vitro studies have shown that these mutations increase CYP11B2 expression and aldosterone production through increased intracellular calcium levels. [10] [11] [12] [13] CACNA1D encodes Cav 1.3, a subunit of L-type calcium channels that normally mediates calcium ion entry into various cell types, including adrenocortical cells.
21 Cav 1.3 contains 4 repeated domains, each of which consists of 6 transmembrane segments (S1-S6). The Cav 1.3 voltage sensor (S4), the cytoplasmic S4 and S5 linker coupling the voltage-sensing domain to the pore and the channel activation gate (S6) have all been reported to harbor activating mutations in APA.
11
A recently developed monoclonal antibody for CYP11B2 22 enabled multiple research groups to identify small CYP11B2-positive cell clusters-termed aldosteroneproducing cell clusters (APCC)-beneath the adrenal capsule. [23] [24] [25] Without CYP11B2 immunohistochemistry, these cells seem histologically identical to the adjacent zona glomerulosa (ZG) cells. 24 We have further demonstrated the presence and age-dependent accumulation of APCC in adrenals from American kidney donors 25, 26 and normotensive Japanese autopsy adrenals. 27 Hypothesizing that APCC has similar mutations to that seen in APA, we performed NGS targeting the complete coding sequence of aldosteroneregulating genes that are commonly mutated in APA. We identified mutations in CACNA1D (preferentially affecting the same residues as in APA) in ≈35% of APCC, 25, 27 suggesting autonomous aldosterone production in APCC similar to that proposed for APA. We further showed that the morphology and mutation spectrum of CYP11B2-expressing micronodules in CT-negative unilateral PA were essentially identical to APCC. 9 Of note, the number of APCC was significantly higher in CT-negative unilateral PA compared with that of normotensive adrenals, 27 supporting APCC as source of aldosterone excess in unilateral PA without CT or grossly identifiable tumors.
Bilateral hyperaldosteronism (BHA) most often presents without detectable masses by CT and is called idiopathic hyperaldosteronism (IHA) but can also be caused by bilateral APA. 28, 29 Here, we hypothesized that IHA aldosterone excess results from increased APCCs compared with normal adrenals. 9 To test this hypothesis, we performed CYP11B2 immunohistochemistry in a unique cohort of adrenals from patients with IHA who underwent adrenalectomy. CYP11B2 immunohistochemistry revealed that while diffuse CYP11B2-expressing hyperplasia was infrequent in our cohort, APCCs were more numerous (and larger) than observed in control adrenals. Furthermore, targeted NGS demonstrated that all IHA adrenals harbored at least 1 APCC or a micro-APA with a somatic mutation in a gene known to dysregulate aldosterone production (most frequently CACNA1D). Together these findings indicate that somatic mutation and APCC accumulation/enlargement may play a role in IHA.
Methods
Most of the data that support the findings of this study are available within the article and in the online-only Data Supplement. The remaining supporting data are available from the corresponding author on reasonable request.
Human IHA Adrenal Glands
We retrospectively reviewed cases with IHA from 2 institutes (Tohoku University, Sendai, Japan and University of Queensland, Brisbane, Australia) and collected 10% formalin-fixed paraffinembedded tissue blocks of resected adrenal glands that met all of the following inclusion criteria of IHA clinical diagnosis per guidelines 30, 31 : (1) patients who were diagnosed with sporadic (nonfamilial) PA and without cortisol cosecretion, (2) patients who were proven to have bilateral hypersecretion of aldosterone by adrenal vein sampling, (3) patients who did not have adrenal masses by computed tomography (CT), and (4) patients who underwent unilateral adrenalectomy.
Adrenal vein sampling methods are described Methods in the online-only Data Supplement. In all cases, the adrenal gland corresponding to the side with the highest aldosterone secretion was resected. Results from this IHA cohort were compared with previously described cohorts of 53 age-matched normotensive adrenals (29 males, 24 females) 27 and 7 adrenals from CT-negative unilateral PA (unilateral APCC; 3 males, 4 females) 9 evaluated similarly.
Patients with IHA are typically treated medically, most commonly with mineralocorticoid receptor (MR) antagonists. Surgery is only offered in exceptional situations, to provide individualized therapy in unique circumstances, such as difficult to control hypertension or hypokalemia, and in rare instances of intolerance to medical therapy. Our cohort consisted of 15, such cases that were identified >30 year period in 2 active PA referral centers; the circumstances Figure 1 . Classification of PA. Primary aldosteronism (PA) is categorized into bilateral and unilateral forms based on the source of aldosterone production evaluated by adrenal vein sampling. Computed tomography (CT)-detectable PA is predominantly caused by aldosterone-producing adenoma (APA), whereas CT-negative unilateral PA is caused by CYP11B2 (aldosterone synthase) expressing aldosterone-producing cell clusters (APCCs). CT-negative bilateral PA, the most common subtype of PA (70%), is referred to as idiopathic hyperaldosteronism (IHA). Herein, examining a rare collection of IHA adrenals and combining histology, immunohistochemistry and next-generation sequencing, we defined the role of somatic mutations in IHA.
for surgical consideration are provided in Table S1 in the online-only Data Supplement.
The research protocol was approved by the local ethics committee/Institutional Review Board at Tohoku University, Sendai, Japan (Approval number: 2016-1-693), University of Queensland, Brisbane, Australia (Approval number: HREC/13/QPAH232), and University of Michigan, Ann Arbor, MI (Approval number: HUM00042749 and HUM00106809). All participants provided written informed consent.
Adrenal Sectioning, Immunohistochemistry, and NGS
Adrenal specimens were fixed in 10% formalin and embedded in paraffin after surgery. Formalin-fixed paraffin-embedded blocks from 1 
Gene
Mutation Frequency Somatic mutations detected in IHA adrenals are shown and ordered by mutation frequency. A number 2 within a box indicates that the case had 2 mutations. Frequency indicates the total number of APCC or microAPA with mutations in the whole cohort. Of the 99 APCC/micro-APA sequenced in the cohort, 58% (57/99) harbored somatic mutations in CACNA1D, 1% (1/99) in KCNJ5 and 42% (41/99) had no mutations in the targeted genes that were sequenced. APA indicates aldosteroneproducing adenomas; APCC, aldosterone-producing cell cluster; and IHA, idiopathic hyperaldosteronism.
* indicates the identified mutation was previously reported in APA. † indicates the mutation was in an APCC. ‡ indicates the mutation was in an APCC and a micro-APA within the same case. § APA reported mutations that have been functionally characterized. ‖ indicates the mutation was in a micro-APA.
adrenal were selected for evaluation based on visual inspection of the block (largest amount of cortical tissue if >1 block was prepared) and availability. Selected blocks were serially sectioned and stained with hematoxylin and eosin (H&E) and CYP11B2 (Millipore, MABS1251) to detect and quantify APCC as previously described. 27 To enable comparison across the cohort (accounting for differences in section size), an APCC score was calculated as APCC number per section divided by the cortex area (cm 2 ). Six micro-APA were observed and included with APCC for data analysis. While being CYP11B2-positive like APCC, these structures had histology that was consistent with an adenoma including nuclear atypia, a fibrous capsule, well-circumscribed margins and disruption of adrenal zonation that was visible by H&E and CYP11B2 immunostaining, as previously described. 9, 32, 33 Targeted NGS (using a panel targeting the complete coding sequence of genes recurrently mutated in APA) was performed as previously described. 27 Detailed methods of sectioning, immunostaining and NGS are described Methods in the online-only Data Supplement.
Statistics
The D'Agostino-Pearson method was used for normality test in each variable. Gaussian variables were reported as mean±SD, and non-Gaussian variables were described as median (interquartile range). Two-sided Spearman rank test as used for correlation between the APCC mutation rate and plasma aldosterone levels. Two-sided Mann-Whitney test was used to compare APCC score and APCC area between IHA, CT-negative unilateral PA, and age-matched normotensive adrenals. P<0.05 was considered a significant difference. PRISM (version 7, GraphPad Software, Inc.) software was used for all statistical calculations.
Results

APCC Number and Area in IHA Adrenals
We collected 15 IHA cases from patients (10 men and 5 women) who underwent unilateral adrenalectomy with available surplus clinical formalin-fixed paraffin-embedded tissue (8 from Tohoku University, 7 from University of Queensland; Figure 1 ; Table S1 ). Clinical information for these cases is described in the Results in the online-only Data Supplement.
By histology, diffuse ZG hyperplasia and diffuse nodular hyperplasia of adrenocortical cells were observed in 13 (87%) and 9 (60%) of the 15 IHA cases, respectively. However, only 4/15 (27%) adrenals had diffuse positive CYP11B2 cells in either the ZG or zona fasciculata, indicating that the histologically observed hyperplastic adrenal cells were not aldosterone-producing cells (Table; Figure 2C and 2D).
In contrast, all IHA adrenals harbored at least 1 CYP11B2-positive APCC, with a total of 104 detected APCC (6.9±4.1 APCC per IHA case; Figure 2A and 2B; Table S1 ). Of the 104 APCC, 6 fulfilled the criteria of micro-APA as described in the Methods and previously 9 (Table S2) . Spironolactone bodies were only detected in APCC but not in the intervening CYP11B2 positive/negative ZG cells.
The median APCC score (APCC number/adrenal cortex area, 6.1 versus 0 /cm 2 ; P<0.0001) and APCC area (0.25 versus 0.16 mm 2 ; P=0.0019) were significantly greater in IHA adrenals versus a similarly evaluated cohort of normotensive adrenals (Figure 3) . In contrast, the median APCC score (P=0.63) and APCC area (P=0.07) in IHA adrenals were not significantly different versus adrenals from CT-negative unilateral PA (Figure 3 ).
NGS on APCC in IHA
To determine the somatic mutation spectrum of aldosteronedriving genes in IHA adrenals, we performed targeted NGS using a stringent 2-panel approach on 99 APCC DNA samples (5/104 samples that did not pass DNA QC metrics were excluded). DNA from intervening CYP11B2 positive and negative ZG regions (2 regions from each case) were also analyzed by NGS, with no somatic mutations detected in intervening ZG regions. In contrast, 14/14 (100%) sequenced cases had at least 1 APCC harboring a known somatic mutation in an aldosterone-driving gene. Specifically, 58% (57/99) and 1% (1/99) of APCC had somatic mutations in CACNA1D and KCNJ5, respectively (Table; Table S2 ). Importantly, the APCC mutation rate per case (number of APCC with mutations/total APCC number) was significantly positively correlated with preoperative plasma aldosterone concentration (r=0.54; P=0.049). No significant differences in age and mutation frequency were observed between samples from the 2 institutes (Results in the online-only Data Supplement).
Of the 58 APCC with a somatic mutation, 38 (66%) harbored mutations previously reported in APA 34 (Table) . In total, 77% (44/57) of the CACNA1D mutations occurred at domains recurrently mutated in APA (9 [16%] 
Discussion
While IHA was labeled as idiopathic in the 1960s, 35 the cause of hyperaldosteronism remains largely unknown, with adrenal cell diffuse hyperplasia traditionally considered the source of excess aldosterone. Although diffuse hyperplasia of ZG cells in IHA adrenals has been reported often, 32,33,36-40 others reports described diffuse hyperplasia of multiple cortex zones concomitant with adrenocortical nodules. 35, 36, 39, [41] [42] [43] [44] Such findings have been referred to as primary cortical hyperplasia (morphologically increased number of ZG and zona fasciculata cells) by some investigators. Importantly, these histological evaluations were performed on limited series without the ability to assess for in situ aldosterone secretory capacity (enabled recently by CYP11B2 IHC). 36, [38] [39] [40] 43, [45] [46] [47] Through a unique cohort of rarely resected adrenals from IHA patients, we demonstrated that most cases did not exhibit hyperplastic adrenocortical cells expressing CYP11B2, inconsistent with the concept of diffuse hyperplasia of aldosterone-producing cells causing IHA. Instead, by CYP11B2 IHC paired with targeted NGS, we observed that all IHA adrenals had small CT-undetectable CYP11B2-positive cell areas (APCCs), which were significantly increased in number and size compared with normal adrenals. In addition, APCC in the IHA adrenals frequently harbored aldosterone-driving somatic mutations, nearly exclusively in CACNA1D, consistent with the somatic mutation spectrum of APCC observed in normal adrenals 27 and CT-negative unilateral PA adrenals. 9 This mutation spectrum is markedly different in APA, where mutations are much more frequent in KCNJ5 versus CACNA1D. [13] [14] [15] [16] [17] [18] [19] [20] Importantly, APCC score, area and mutation spectrum in IHA were essentially identical to those we previously described in CT-negative unilateral PA 9 , supporting APCC as a common cause of both unilateral and bilateral forms of CT-negative PA. Taken together, our findings support recurrent somatic CACNA1D mutations in APCC as the main cause of autonomous aldosterone production in IHA.
A crucial and necessary pharmacotherapy for IHA are MR blockade. Although MR blockade is the only currently available specific treatment for IHA, in some cases these drugs provide insufficient blood pressure control and side effects. [48] [49] [50] [51] In addition, alternative antihypertensive drugs, including calcium channel blockers, have not been extensively evaluated in IHA. 30 Thus, understanding the pathobiology of IHA to develop additional targeted therapeutic approaches, when MR blockade is not sufficient, could be beneficial. Intriguingly, CACNA1D, which was the most frequently mutated gene in IHA, encodes an L-type calcium channel that is inhibited by Food and Drug Administration approved calcium channel blocker. 52 In addition, a recent in vitro study showed that aldosterone levels were significantly decreased by nifedipine in human adrenocortical cells transfected with mutated CACNA1D. 53 These results support CACNA1D mutationstimulated aldosterone production in APCC as a potential therapeutic target that may directly inhibit the mechanism of increased aldosterone production in CT-negative PA. The positive correlation between APCC CACNA1D mutation rate and preoperative aldosterone levels suggests that calcium channel blocker-targeted therapy may be more effective for IHA patients with higher aldosterone secretion, who are the most likely to need antihypertensive drugs beyond MR blockers.
Limitations of the present study includes the small numbers of the IHA adrenals available, and the unique nature of the patients requiring surgery for bilateral PA. Therefore, the results shown in the present study need to be confirmed in a larger cohort, potentially in a multicenter study using adrenals from well-characterized CT-negative unilateral patients that continue to have PA after surgery. The specific patients used in this study may also impact the findings, as many were severe IHA cases that required additional pharmacotherapy to complement the MR-blockade approach and were often refractory to all therapies. The current results, however, remain foundational by demonstrating that IHA adrenals have gene mutations and a buildup of APCC. In addition, the study provides the methods to localize aldosterone-producing cells, isolate DNA, and define mutations using formalin-fixed paraffin-embedded tissues, providing a platform for others to use archival surgical IHA adrenals and expand such studies.
In conclusion, our results support increased autonomous aldosterone production driven by somatic mutations in aldosterone-regulating genes (nearly exclusively CACNA1D) and APCC accumulation/enlargement as an underlying cellular and molecular cause of IHA. Coupled with previous studies in APA and CT-negative unilateral PA, our findings in IHA suggest that the majority of PA results from somatic mutations in aldosterone-regulating genes that influence intracellular calcium homeostasis. Importantly, as opposed to APA, CT-negative PA is primarily associated with mutations in CACNA1D. The availability of widely used antihypertensive calcium channel blockers supports investigations into the efficacy of these drugs to inhibit aldosterone production in IHA.
Perspectives
Worldwide, >100 million patients had IHA, yet its underlying cause remain unknown. In this article, we show that IHA adrenals have expansion/enlargement of aldosteroneproducing cells (APCCs) with somatic gene mutations in the L-type calcium channel, CACNA1D. Importantly, these genetic findings provide a potential cause for the most common subtype of PA, as well as the potential for rapid translation to clinical applications. Combined with previous studies of aldosterone-producing adenomas, this study supports somatic mutation-harboring adrenal cell lesions as the underlying cause of the vast majority of primary aldosteronism.
